Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$9.95 +9.0%	$9.78	$5.03 ▼ $14.44	$854.61M	0.83	1.12 million shs	1.86 million shs
KURA Kura Oncology	$9.57 +4.7%	$7.54	$5.41 ▼ $19.73	$830.68M	0.32	1.50 million shs	1.75 million shs
OCS Oculis	$17.57 +0.6%	$17.51	$12.48 ▼ $23.08	$767.14M	0.29	40,838 shs	20,345 shs
SXTC China SXT Pharmaceuticals	$1.66 +0.5%	$1.62	$0.95 ▼ $7.84	$192.49M	1.36	1.61 million shs	13,623 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	+1.33%	+7.41%	-3.69%	-14.83%	+61.45%
KURA Kura Oncology	-0.65%	+9.33%	+14.97%	+54.65%	-50.59%
OCS Oculis	+0.40%	-0.17%	+8.17%	-7.83%	+42.73%
SXTC China SXT Pharmaceuticals	+1.23%	+3.77%	+16.20%	-9.59%	-74.06%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$9.95 +9.0%	$9.78	$5.03 ▼ $14.44	$854.61M	0.83	1.12 million shs	1.86 million shs
KURA Kura Oncology	$9.57 +4.7%	$7.54	$5.41 ▼ $19.73	$830.68M	0.32	1.50 million shs	1.75 million shs
OCS Oculis	$17.57 +0.6%	$17.51	$12.48 ▼ $23.08	$767.14M	0.29	40,838 shs	20,345 shs
SXTC China SXT Pharmaceuticals	$1.66 +0.5%	$1.62	$0.95 ▼ $7.84	$192.49M	1.36	1.61 million shs	13,623 shs

10 Best Stocks to Own: Fall 2025

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	+1.33%	+7.41%	-3.69%	-14.83%	+61.45%
KURA Kura Oncology	-0.65%	+9.33%	+14.97%	+54.65%	-50.59%
OCS Oculis	+0.40%	-0.17%	+8.17%	-7.83%	+42.73%
SXTC China SXT Pharmaceuticals	+1.23%	+3.77%	+16.20%	-9.59%	-74.06%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	2.33	Hold	$44.00	342.21% Upside
KURA Kura Oncology	2.69	Moderate Buy	$24.10	151.83% Upside
OCS Oculis	3.00	Buy	$35.75	103.47% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SXTC, OCS, AVXL, and KURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/1/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$46.00
9/30/2025	KURA Kura Oncology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/27/2025	AVXL Anavex Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/27/2025	KURA Kura Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/27/2025	OCS Oculis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/27/2025	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/10/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$42.00
9/10/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$46.00
9/4/2025	KURA Kura Oncology	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral
8/27/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$46.00
8/27/2025	OCS Oculis	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$36.00

(Data available from 10/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
KURA Kura Oncology	$53.88M	15.42	N/A	N/A	$5.32 per share	1.80
OCS Oculis	N/A	N/A	N/A	N/A	$1.91 per share	N/A
SXTC China SXT Pharmaceuticals	$1.74M	110.63	N/A	N/A	$21.35 per share	0.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.57	N/A	N/A	N/A	N/A	-45.67%	-40.21%	11/28/2025 (Estimated)
KURA Kura Oncology	-$173.98M	-$2.26	N/A	N/A	N/A	N/A	-52.32%	-29.59%	11/6/2025 (Estimated)
OCS Oculis	-$97.43M	-$2.67	N/A	N/A	N/A	-13,958.12%	-90.31%	-67.85%	11/6/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.30M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest SXTC, OCS, AVXL, and KURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	OCS Oculis	-$0.53	-$0.59	-$0.06	-$0.59	$0.14 million	$0.25 million
8/12/2025	Q3 2025	AVXL Anavex Life Sciences	-$0.13	-$0.16	-$0.03	-$0.16	N/A	N/A
8/7/2025	Q2 2025	KURA Kura Oncology	$0.15	-$0.75	-$0.90	-$0.75	$64.95 million	$15.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	8.93	8.93
KURA Kura Oncology	0.02	6.16	6.16
OCS Oculis	0.01	4.55	4.55
SXTC China SXT Pharmaceuticals	0.01	3.54	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
KURA Kura Oncology	N/A
OCS Oculis	22.30%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.40%
KURA Kura Oncology	6.40%
OCS Oculis	N/A
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.89 million	76.10 million	Optionable
KURA Kura Oncology	130	86.80 million	81.24 million	Optionable
OCS Oculis	2	43.66 million	N/A	Not Optionable
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable

SXTC, OCS, AVXL, and KURA Headlines

Recent News About These Companies

Short Interest in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Expands By 607.4%

October 1 at 5:27 AM | marketbeat.com

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Update

September 16, 2025 | marketbeat.com

China SXT Pharmaceuticals Full Year 2025 Earnings: US$2.32 loss per share (vs US$28.58 loss in FY 2024)

August 2, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Inc. (SXTC) Stock Price Today - WSJ

July 30, 2025 | wsj.com

China SXT Pharmaceuticals, Inc. (SXTC) - Yahoo Finance

July 4, 2025 | sg.finance.yahoo.com

China SXT Pharmaceuticals Inc News (SXTC) - Investing.com

June 25, 2025 | investing.com

China SXT Pharmaceuticals Issues 90 Million Shares Following Warrant Exercise

June 16, 2025 | tipranks.com

China SXT Pharmaceuticals Inc Ordinary Shares

April 23, 2025 | morningstar.comM

China SXT Pharmaceuticals Reports Financial Results Amid Regulatory Challenges

March 28, 2025 | tipranks.com

China SXT Pharmaceuticals Optimizes Capital Structure with Warrant Exchange

March 19, 2025 | tipranks.com

China SXT Pharmaceuticals regains compliance with Nasdaq

March 17, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq’s Minimum Bid Price Deficiency

March 17, 2025 | finance.yahoo.com

China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

March 17, 2025 | globenewswire.com

China SXT Pharmaceuticals Inc trading resumes

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, volatility trading pause

February 25, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Inc trading halted, news pending

February 24, 2025 | markets.businessinsider.com

China SXT Pharmaceuticals Announces New Securities Purchase Agreement

January 27, 2025 | msn.com

China SXT Pharmaceuticals Inc (SXTC) Stock’s 0.02% Increase This Year: What’s the Story?

January 7, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock Price Reaches $0.51: What Factors Are Influencing This Level?

January 1, 2025 | bovnews.comB

China SXT Pharmaceuticals Inc (SXTC) Stock: Greater Than Its Current Valuation?

December 26, 2024 | bovnews.comB

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

October 7, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, OCS, AVXL, and KURA Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$9.95 +0.82 (+8.98%)

Closing price 04:00 PM Eastern

Extended Trading

$9.90 -0.05 (-0.54%)

As of 05:29 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Kura Oncology NASDAQ:KURA

$9.57 +0.43 (+4.70%)

Closing price 04:00 PM Eastern

Extended Trading

$9.43 -0.14 (-1.46%)

As of 05:04 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Oculis NASDAQ:OCS

$17.57 +0.10 (+0.57%)

Closing price 04:00 PM Eastern

Extended Trading

$17.55 -0.02 (-0.11%)

As of 04:04 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.66 +0.01 (+0.55%)

Closing price 03:50 PM Eastern

Extended Trading

$1.61 -0.05 (-2.95%)

As of 04:48 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTC, OCS, AVXL, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTC, OCS, AVXL, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTC, OCS, AVXL, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, OCS, AVXL, and KURA Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

Kura Oncology NASDAQ:KURA

Oculis NASDAQ:OCS

China SXT Pharmaceuticals NASDAQ:SXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SXTC, OCS, AVXL, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SXTC, OCS, AVXL, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SXTC, OCS, AVXL, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, OCS, AVXL, and KURA Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

Kura Oncology NASDAQ:KURA

Oculis NASDAQ:OCS

China SXT Pharmaceuticals NASDAQ:SXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools